General Aspects of Chemotherapy Including “Biologic Agents”
暂无分享,去创建一个
[1] R. Kurzrock,et al. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Kesari,et al. Glioma stem cell signaling: therapeutic opportunities and challenges , 2010, Expert review of anticancer therapy.
[3] J. Sampson,et al. Immunotherapy Approaches for Malignant Glioma From 2007 to 2009 , 2010, Current neurology and neuroscience reports.
[4] W. Mason,et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Steeg,et al. Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer , 2009, Pharmaceutical Research.
[6] J. Groot,et al. Improving the prognosis for patients with glioblastoma: the rationale for targeting Src , 2009, Journal of Neuro-Oncology.
[7] K. Black,et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model , 2008, Brain Research.
[8] J. Herman,et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Wen,et al. Bevacizumab for recurrent malignant gliomas , 2008, Neurology.
[10] Darell D. Bigner,et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.
[11] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[12] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[13] David J. Yang,et al. Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.
[14] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[15] Cynthia Hawkins,et al. Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.
[16] M. Prados,et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. , 2003, Neuro-oncology.
[17] T. Batchelor,et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] W. Pardridge. Blood-brain barrier drug targeting: the future of brain drug development. , 2003, Molecular interventions.
[19] I. Weinstein. Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.
[20] N. Rainov. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. , 2000, Human gene therapy.
[21] L. Rorke,et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. , 1994, Journal of neurosurgery.